Invesco Ltd. Lowers Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Invesco Ltd. decreased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,584,434 shares of the company's stock after selling 57,996 shares during the period. Invesco Ltd. owned about 6.01% of Twist Bioscience worth $166,569,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Twist Bioscience by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after purchasing an additional 189,791 shares during the period. ARK Investment Management LLC grew its stake in shares of Twist Bioscience by 4.4% during the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock valued at $260,040,000 after acquiring an additional 237,772 shares during the period. State Street Corp increased its holdings in Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company's stock worth $143,101,000 after acquiring an additional 526,028 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in Twist Bioscience by 54.6% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock worth $69,972,000 after acquiring an additional 532,040 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Twist Bioscience by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company's stock valued at $63,895,000 after buying an additional 6,908 shares in the last quarter.

Remove Ads

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 806 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $39,776.10. Following the sale, the insider now owns 112,221 shares in the company, valued at $5,538,106.35. This trade represents a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Paula Green sold 1,259 shares of Twist Bioscience stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $62,131.65. Following the sale, the senior vice president now owns 132,014 shares of the company's stock, valued at approximately $6,514,890.90. This trade represents a 0.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,796 shares of company stock worth $1,077,383 over the last quarter. Insiders own 3.01% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on TWST. Barclays lowered their price objective on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Guggenheim set a $50.00 price target on Twist Bioscience in a research note on Friday, March 28th. JPMorgan Chase & Co. increased their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a report on Tuesday, February 4th. Robert W. Baird upped their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 4th. Finally, Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $52.80.

Twist Bioscience Trading Down 0.8 %

Shares of NASDAQ:TWST traded down $0.32 during trading on Tuesday, reaching $39.50. The company's stock had a trading volume of 828,998 shares, compared to its average volume of 981,464. The stock has a market capitalization of $2.36 billion, a PE ratio of -11.69 and a beta of 2.34. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The firm's 50 day simple moving average is $41.27 and its two-hundred day simple moving average is $44.57.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $88.70 million during the quarter, compared to analysts' expectations of $86.96 million. During the same quarter in the previous year, the business earned ($0.75) EPS. The company's quarterly revenue was up 24.1% on a year-over-year basis. On average, research analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.